MOTS-c

MOTS-c is a mitochondrial-derived peptide composed of 16 amino acids that regulates cellular energy metabolism, promotes metabolic homeostasis, and has demonstrated effects on insulin sensitivity, fat metabolism, bone health, and longevity.

MOTS-c is a mitochondrial-derived peptide (MDP) composed of 16 amino acids, encoded by the 12S rRNA gene of the mitochondrial genome. It plays a critical role in cellular metabolic regulation by modulating glucose metabolism, insulin sensitivity, and cellular stress response through AMPK-dependent pathways.

Overview

MOTS-c was first identified in 2015 by researchers at the USC Leonard Davis School of Gerontology. It represents a class of bioactive peptides derived from short open reading frames within mitochondrial DNA. Unlike most mitochondrial proteins, MOTS-c acts as a retrograde signaling molecule that communicates mitochondrial status to the nucleus and other cellular compartments. Research has shown this peptide to improve exercise capacity, reduce obesity and insulin resistance, and influence disease processes such as osteoporosis and cardiovascular dysfunction.

Mechanism of Action

MOTS-c targets the methionine-folate cycle, increases AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) levels, and activates AMPK, a master regulator of cellular energy homeostasis. AMPK activation drives glucose and fatty acid uptake independently of the insulin signaling pathway. Under metabolic stress, MOTS-c translocates from the cytoplasm to the nucleus, where it regulates genes involved in glucose restriction and antioxidant responses (Kim et al., 2018). This dual-compartment activity positions MOTS-c as a unique mitochondrial-nuclear signaling peptide.

Reconstitution Calculator

MOTS-c

MOTS-c is a mitochondrial-derived peptide (MDP) composed of 16 amino acids, enco

Draw Volume
1.000mL
Syringe Units
100units
Concentration
5,000mcg/mL
Doses / Vial
2doses
Vial Total
10mg
Waste / Vial
0mcg
Syringe Cap.
100units · 1mL
Recommended Schedule
M
T
W
T
F
S
S
Frequency2-3x/week
TimingMorning
Cycle8-12 weeks
NoteExercise mimetic; 5mg 2-3x/week is common protocol
How to reconstitute
Gather & prepare
1/6Gather & prepare

Set up a clean workspace with all supplies ready.

1.Wash hands thoroughly, put on disposable gloves
2.Your 10mg peptide vial (lyophilized powder)
3.Bacteriostatic water (you'll need 2mL)
4.A 3–5mL syringe with 21–25 gauge needle for reconstitution
5.Alcohol swabs (70% isopropyl)
Use bacteriostatic water (0.9% benzyl alcohol) for multi-dose vials. Sterile water is only safe for single-use.
Supply Planner

3x / week for weeks

·
·
·
·
·
·
6vials
12 doses4 days/vial
Cost Breakdown
Vial price
$0.00per dose
$0.00 /week$0 /month
Store 2-8°C30 day shelf lifeSwirl gentlyFor research purposes only

Research

Exercise Mimicry

MOTS-c recapitulates multiple molecular signatures of exercise: AMPK activation, enhanced mitochondrial biogenesis via PGC-1alpha, increased glucose uptake in skeletal muscle, and improved fatty acid oxidation. Kim et al. (2018) showed that exercise increases circulating MOTS-c levels in humans and that MOTS-c administration improves physical capacity in sedentary mice, positioning it as a bona fide exercise-responsive mitokine (Kim et al., 2018).

Aging and Longevity

Circulating MOTS-c levels decline with age in both mice and humans, correlating with metabolic dysfunction and reduced exercise capacity. MOTS-c administration in aged mice restores insulin sensitivity, improves physical performance, and reverses age-dependent metabolic decline. The mitochondrial encoding of MOTS-c means its expression is subject to mitochondrial DNA copy number changes, heteroplasmy, and maternal inheritance patterns, adding genetic complexity to age-related decline.

Obesity and Fat Metabolism

MOTS-c prevents obesity in high-fat diet-fed mice by increasing skeletal muscle fatty acid oxidation and thermogenesis. The S6K1 inhibition mechanism is critical here: S6K1 normally activates lipogenic gene programs via SREBP1c, and MOTS-c-mediated S6K1 suppression shifts the metabolic balance from lipogenesis to lipolysis and beta-oxidation.

Muscle Metabolism

Research in mice indicates that MOTS-c can reverse age-dependent insulin resistance in muscles by improving skeletal muscle response to AMPK activation, which increases the expression of glucose transporters (Lee et al., 2016). This activation is independent of the insulin pathway and offers an alternative means of boosting glucose uptake by muscles when insulin is ineffective or insufficient. The net result is improved muscle function, enhanced muscle growth, and decreased functional insulin resistance.

Insulin Sensitivity

Research measuring MOTS-c levels in insulin-sensitive and insulin-resistant individuals has shown that the peptide is associated with insulin sensitivity only in lean individuals, suggesting MOTS-c may be important in the pathogenesis but not the maintenance of insulin insensitivity (Cataldo et al., 2018). Scientists speculate that changes in MOTS-c levels could act as an early warning sign of potential insulin resistance, and supplementation in this setting could help stave off the development of diabetes.

Osteoporosis

MOTS-c appears to play a role in the synthesis of type I collagen by osteoblasts. Research in osteoblast cell lines shows that MOTS-c regulates the TGF-beta/SMAD pathway responsible for osteoblast health and survival, improving type I collagen synthesis and therefore bone strength and integrity (Che et al., 2019).

Additional research has revealed that MOTS-c promotes differentiation of bone marrow stem cells via the same TGF-beta/SMAD pathway, directly leading to increased osteogenesis (Hu & Chen, 2018). Thus, MOTS-c both protects existing osteoblasts and promotes their development from stem cells.

Longevity

Research has identified a specific variant in the MOTS-c gene (m.1382A>C) that substitutes a glutamate residue for the lysine normally found at position 14. This variant is found exclusively in people with Northeast Asian ancestry and is associated with exceptional longevity in Japanese populations (Fuku et al., 2015). The mechanism by which this substitution affects function remains under investigation, but the structural change likely alters both peptide conformation and receptor interactions.

Metabolic Regulation and Insulin Sensitization

Lee et al. (2015) demonstrated that MOTS-c administration prevents age-dependent and high-fat diet-induced insulin resistance in mice. MOTS-c-treated mice showed improved glucose tolerance, reduced fat accumulation, and increased insulin sensitivity compared to controls. These effects were mediated through AMPK-dependent inhibition of the mTOR/S6K1 axis and enhanced fatty acid oxidation in skeletal muscle (Lee et al., 2015).

Nuclear Gene Regulation

Reynolds et al. (2021) demonstrated that MOTS-c undergoes nuclear translocation under stress conditions (glucose restriction, oxidative stress, exercise). In the nucleus, MOTS-c interacts with chromatin and regulates expression of genes containing antioxidant response elements (AREs), including NRF2-target genes involved in glutathione metabolism, detoxification, and mitochondrial quality control. This finding transformed understanding of MOTS-c from a simple metabolic regulator to a direct transcriptional modulator (Reynolds et al., 2021).

Fat Metabolism

Research in mice has shown that low estrogen levels lead to increased fat mass and adipose tissue dysfunction, increasing the risk of insulin resistance. Supplementing mice with MOTS-c increases brown fat function and reduces adipose tissue accumulation while preventing adipose inflammation that typically precedes insulin resistance (Lu et al., 2019).

MOTS-c's influence on fat metabolism is mediated largely through AMPK pathway activation, which drives fatty acid uptake and oxidation. Research suggests that MOTS-c can leave the mitochondria and translocate to the nucleus where it affects nuclear gene expression, regulating genes involved in glucose restriction and antioxidant responses (Kim et al., 2018). Studies on MOTS-c as a regulator of plasma metabolites have further demonstrated its role in enhancing insulin sensitivity (Kim et al., 2019).

Research has led to a hypothesis that dysregulation of fat metabolism in mitochondria may result in a lack of fat oxidation, leading to higher circulating fat levels and compensatory hyperinsulinemia. MOTS-c supplementation in rats prevents mitochondrial dysfunction and fat accumulation even on a high-fat diet (Crescenzo et al., 2016).

Heart Health

Research measuring MOTS-c levels in humans undergoing coronary angiography has revealed that patients with lower circulating MOTS-c have higher levels of endothelial cell dysfunction. Supplementing rats with MOTS-c sensitizes endothelial cells to signaling molecules like acetylcholine, improving endothelial function and microvascular blood vessel function (Qin et al., 2018).

MOTS-c is not alone among mitochondria-derived peptides in affecting heart health. Research suggests that at least three MDPs play roles in protecting cardiac cells against stress and inflammation, and MDP dysregulation may be an important factor in cardiovascular disease development (Yang et al., 2019).

Safety Profile

MOTS-c is an endogenous peptide naturally produced within human mitochondria, which provides a favorable theoretical safety profile. In animal studies, exogenous MOTS-c administration has not demonstrated significant adverse effects at the doses used in published research. However, no formal human clinical trials have established a comprehensive safety profile. As a metabolically active peptide that influences AMPK signaling, glucose metabolism, and gene expression, potential interactions with diabetes medications and metabolic therapies should be considered. Long-term effects of exogenous supplementation remain uncharacterized.

Animal Study Dosing

Most published MOTS-c research has been conducted in murine models. Lee et al. (2015) used intraperitoneal (IP) injections of MOTS-c at 5 mg/kg/day in C57BL/6 mice fed a high-fat diet for 8 weeks, demonstrating significant reductions in obesity and insulin resistance. Kim et al. (2018) administered 5 mg/kg IP over 12-week periods to characterize nuclear translocation and metabolic gene regulation. In osteoporosis models, Hu & Chen (2018) used 5 mg/kg/day IP in ovariectomized rats for 8 weeks, showing significant bone density improvements.

Exercise and Aging Studies

Kumagai et al. (2022) examined the MOTS-c K14Q variant in exercise physiology, measuring endogenous MOTS-c levels in healthy young adults before and after acute exercise bouts. Plasma MOTS-c levels increased 1.5-2 fold following maximal exercise testing. In aging mouse models, Reynolds et al. (2021) administered 15 mg/kg IP three times weekly for 2 weeks in 22-month-old mice and observed improvements in treadmill endurance, grip strength, and gait performance comparable to younger animals.

Human Observational Data

Cataldo et al. (2018) measured circulating MOTS-c levels in 78 Pima Indian subjects (37 insulin-sensitive, 41 insulin-resistant) using ELISA-based quantification. Mean plasma MOTS-c was significantly higher in lean insulin-sensitive individuals (~0.8 ng/mL) compared to obese insulin-resistant individuals (~0.4 ng/mL). No interventional human clinical trials with exogenous MOTS-c have been published to date.

Pharmacokinetic Profile

MOTS-c — Pharmacokinetic Curve

Subcutaneous injection
0%25%50%75%100%0m30m1h1.5h2h2.5hTimeConcentration (% peak)T_max 32mT_1/2 30m
Half-life: 30mT_max: 1hDuration shown: 2.5h

Quick Start

Typical Dose
Start 5mg daily, increase to 10-15mg based on goals
Frequency
Daily for metabolic support, or 3x weekly for anti-aging
Route
Subcutaneous injection
Cycle Length
4-12 weeks depending on goals
Storage
Refrigerate reconstituted solution at 2-8°C, use within 14 days

Molecular Structure

2D Structure
MOTS-c molecular structure
Molecular Properties
Formula
C101H152N28O22S2
Weight
2174.6 Da
Length
16 amino acids
CAS
1627580-64-6
PubChem CID
146675088
Exact Mass
2174.1111 Da
LogP
-3.9
TPSA
890 Ų
H-Bond Donors
31
H-Bond Acceptors
29
Rotatable Bonds
73
Complexity
4510
Identifiers (SMILES, InChI)
InChI
InChI=1S/C101H152N28O22S2/c1-7-57(4)83(96(148)126-76(50-58-19-9-8-10-20-58)92(144)127-78(52-60-30-34-63(131)35-31-60)97(149)129-46-18-27-79(129)95(147)122-69(25-16-44-112-100(107)108)86(138)118-67(23-13-14-42-102)87(139)124-74(49-56(2)3)91(143)123-73(98(150)151)26-17-45-113-101(109)110)128-94(146)75(51-59-28-32-62(130)33-29-59)116-81(133)55-115-85(137)72(41-48-153-6)121-90(142)71(37-39-82(134)135)119-89(141)70(36-38-80(104)132)120-93(145)77(53-61-54-114-66-22-12-11-21-64(61)66)125-88(140)68(24-15-43-111-99(105)106)117-84(136)65(103)40-47-152-5/h8-12,19-22,28-35,54,56-57,65,67-79,83,114,130-131H,7,13-18,23-27,36-53,55,102-103H2,1-6H3,(H2,104,132)(H,115,137)(H,116,133)(H,117,136)(H,118,138)(H,119,141)(H,120,145)(H,121,142)(H,122,147)(H,123,143)(H,124,139)(H,125,140)(H,126,148)(H,127,144)(H,128,146)(H,134,135)(H,150,151)(H4,105,106,111)(H4,107,108,112)(H4,109,110,113)/t57-,65-,67-,68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,83-/m0/s1
InChIKeyWYTHCOXVWRKRAH-LOKRTKBUSA-N

Research Indications

Metabolic

Strong Evidence
Insulin Resistance

Improves insulin sensitivity by ~30% in animal studies through AMPK activation.

Strong Evidence
Type 2 Diabetes Support

Restores metabolic function via insulin receptor sensitization.

Good Evidence
Obesity Prevention

Promotes fatty acid oxidation despite identical caloric intake.

Anti-Aging

Good Evidence
Age-Related Decline Reversal

Reverses age-dependent physical decline in animal models.

Good Evidence
Mitochondrial Biogenesis

Enhances mitochondrial function via PGC-1α activation.

Good Evidence
Lifespan Extension

6.4% median lifespan extension observed in mice studies.

Exercise Performance

Moderate Evidence
Running Performance

12-15% improvement in running performance from single dose in studies.

Moderate Evidence
Muscle Homeostasis

Exercise induced 11.9-fold increase in skeletal muscle MOTS-c.

Moderate Evidence
Recovery Support

Supports muscle recovery and adaptation to exercise.

Research Protocols

subcutaneous Injection

Mitochondria-derived peptide administered subcutaneously with gradual titration.

GoalDoseFrequency
Loading phase200 mcgOnce daily
Escalation 1400 mcgOnce daily
Escalation 2600 mcgOnce daily
Escalation 3800 mcgOnce daily
Full dose1,000 mcgOnce daily
Reconstitution Guide (10mg vial + 3mL BAC water)
  1. Wipe vial tops with alcohol swab
  2. Draw 3.0 mL bacteriostatic water into syringe
  3. Inject slowly down the inside wall of the peptide vial
  4. Gently swirl to dissolve — never shake
  5. Resulting concentration: 3.33 mg/mL
  6. For 200 mcg dose: draw 6 units (0.06 mL)
  7. For 600 mcg dose: draw 18 units (0.18 mL)
  8. For 1,000 mcg dose: draw 30 units (0.30 mL)
  9. Store reconstituted vial refrigerated at 2-8°C

intraperitoneal Injection

- Routes: Intraperitoneal injection (mice); subcutaneous injection anticipated for human translation.

GoalDoseFrequency
General Research Protocol5 mgDaily
General Research Protocol5 mgPer protocol

Interactions

Peptide Interactions

Precursorssynergistic

MOTS-c's activation of PGC-1alpha and mitochondrial biogenesis programs could synergize with NAD+ precursors (nicotinamide mononucleotide or nicotinamide riboside) that support sirtuin-dependent mitochondrial quality control. Both approaches target age-related mitochondrial decline through comple...

Humaninsynergistic

Both are mitochondrial-derived peptides (MDPs) encoded in neighboring regions of the mitochondrial genome (12S vs 16S rRNA). Humanin is primarily cytoprotective (anti-apoptotic, neuroprotective) while MOTS-c is primarily metabolic. Combining two MDPs may recapitulate the full retrograde signaling program of healthy mitochondria.

Spermidinesynergistic
  • Both activate AMPK through distinct upstream mechanisms (MOTS-c via AICAR/folate disruption; spermidine via EP300 inhibition). Additionally, MOTS-c promotes mitochondrial biogenesis (building new mitochondria) while spermidine promotes mitophagy (clearing damaged mitochondria) -- a complementary "build and demolish" approach to mitochondrial quality control.
Epithalonsynergistic

MOTS-c targets metabolic aging via AMPK/mTOR, while Epithalon targets replicative aging via telomerase. Both undergo nuclear translocation to regulate gene expression, but through different promoter elements (AREs vs immune/circadian gene promoters). Multi-target geroprotection.

What to Expect

What to Expect

Week 1-2

AMPK pathway activation; initial glucose tolerance improvements

Week 2-4

Enhanced exercise capacity; improved insulin sensitivity

Week 4-8

Sustained metabolic benefits; potential body composition changes

Week 8-12

Maximum mitochondrial function enhancement; metabolic flexibility

Safety Profile

Common Side Effects

  • Generally well-tolerated in animal studies with minimal side effects
  • Mild injection site reactions (redness, swelling)

Contraindications

  • Pregnancy or breastfeeding
  • WADA prohibited substance (banned for athletic competition)
  • Limited long-term human safety data

Discontinue If

  • Severe allergic reactions or anaphylaxis
  • Recurrent hypoglycemia (<50 mg/dL)
  • Persistent severe injection site reactions
  • Unexplained weight loss >10% of baseline

Quality Indicators

What to look for

  • White to off-white powder with uniform appearance indicating proper storage
  • Clear, colorless solution without particles after reconstitution
  • Sequence verification (MRWQEMGYIFYPRKLR) with CoA >95% purity by RP-HPLC

Caution

  • Limited human clinical data - start conservatively
  • WADA banned substance - not for competitive athletes

Red flags

  • Discolored powder or solution
  • Cloudy solution after reconstitution
  • No certificate of analysis available

Frequently Asked Questions

References (26)

  1. [18]
    Cataldo et al *J Investig Med* J Investig Med (2018)
  2. [21]
    Fuku et al *Aging Cell* Aging Cell (2015)
  3. [1]
    Obesity and Insulin Sensitivity Study - Lee et al. (2015)
  4. [2]
    Physical Performance Across Age Groups - Reynolds et al. (2021)
  5. [3]
    Nuclear Translocation Study - Kim et al. (2018)
  6. [4]
    Running Performance Study - Hyatt et al. (2022)
  7. [5]
    Gestational Diabetes Study - Yin et al. (2022)
  8. [9]
  9. [12]
  10. [19]
    Che et al *Eur Rev Med Pharmacol Sci* Eur Rev Med Pharmacol Sci (2019)
  11. [22]
    Qin et al *Int J Cardiol* Int J Cardiol (2018)
  12. [23]
    Yang et al *Biomed Pharmacother* Biomed Pharmacother (2019)
  13. [16]
    Kim et al *Physiol Rep* Physiol Rep (2019)
  14. [17]
    Crescenzo et al *Eur J Nutr* Eur J Nutr (2016)
  15. [6]
  16. [7]
  17. [8]
  18. [10]
  19. [11]
  20. [27]
    D'Souza et al — Mitochondrial-derived peptides in energy metabolism Trends Endocrinol Metab (2023)
  21. [13]
    Lee et al *Free Radic Biol Med* Free Radic Biol Med (2016)
  22. [26]
  23. [14]
    Lu et al *J Mol Med* J Mol Med (2019)
  24. [15]
    Kim et al *Cell Metab* Cell Metab (2018)
  25. [25]
    Kumagai et al — The MOTS-c K14Q variant enhances exercise capacity and is associated with longevity iScience (2022)
  26. [24]
Updated 2026-03-08Sources: jabronistore-wiki, peptide-wiki-mdx, pep-pedia, pubchem, peptide-wiki-mdx-v2

On this page